People with COPD have lots of questions. RELIANCE was designed to help get answers.
RELIANCE enrolled 1,032 people across the country. It is now closed for enrollment.
Over the last fifteen years, 20,000 patients have joined studies to prove azithromycin and roflumilast help people with COPD. RELIANCE needed 1250 people to know which drug works best for whom: for current smokers, former smokers, women, men, and for patients with other diseases.
RELIANCE was a head-to-head comparison of these two medicines to learn how long-term use improves the lives of people with COPD.
Keeping people out of the hospital and reducing deaths
Being hospitalized for a COPD attack is a serious problem. If we can reduce hospitalizations for COPD, we know people live longer, feel better. What we don’t know is which drug works better to do this: roflumilast or azithromycin. We also don’t know which drug works best if you are a current or former smoker.
RELIANCE could change COPD care for good
People who joined RELIANCE helped determine what care for people with COPD should include. RELIANCE provided a chance to make a difference for people with COPD.
What did participation involve?
Eligibility criteria
Patients talked to their doctor at their clinic appointment to determine if they were a good fit for RELIANCE.
Together they decided if RELIANCE was the right study for them.
What was RELIANCE really about?
For patients who decided to join, a clinician who was part of RELIANCE reviewed the study at a clinic appointment.
Click the image below for an overview of the study.
Point your phone camera at the QR code below to add RELIANCE to your smart phone’s contacts.
